William Blair Initiates Coverage On ON Semiconductor with Outperform Rating
William Blair analyst Jed Dorsheimer initiates coverage on ON Semiconductor (NASDAQ:ON) with a Outperform rating.
Roth Capital Initiates Coverage On Perpetua Resources with Buy Rating, Announces Price Target of $4
Roth Capital analyst Mike Niehuser initiates coverage on Perpetua Resources (NASDAQ:PPTA) with a Buy rating and announces Price Target of $4.
Jefferies Assumes MSC Industrial Direct Co at Hold, Announces Price Target of $84
Jefferies analyst Stephen Volkmann assumes MSC Industrial Direct Co (NYSE:MSM) with a Hold rating and announces Price Target of $84.
Jefferies Assumes Fastenal at Hold, Announces Price Target of $50
Jefferies analyst Stephen Volkmann assumes Fastenal (NASDAQ:FAST) with a Hold rating and announces Price Target of $50.
William Blair Initiates Coverage On Aehr Test Systems with Outperform Rating
William Blair analyst Jed Dorsheimer initiates coverage on Aehr Test Systems (NASDAQ:AEHR) with a Outperform rating.
Susquehanna Initiates Coverage On SunPower with Positive Rating, Announces Price Target of $25
Susquehanna analyst Biju Perincheril initiates coverage on SunPower (NASDAQ:SPWR) with a Positive rating and announces Price Target of $25.
B of A Securities Initiates Coverage On Digital Turbine with Buy Rating, Announces Price Target of $24
B of A Securities analyst Omar Dessouky initiates coverage on Digital Turbine (NASDAQ:APPS) with a Buy rating and announces Price Target of $24.
SVB Leerink Initiates Coverage On CTI BioPharma with Outperform Rating, Announces Price Target of $13
SVB Leerink analyst Andrew Berens initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Outperform rating and announces Price Target of $13.
Deutsche Bank Initiates Coverage On Avient with Buy Rating, Announces Price Target of $40
Deutsche Bank analyst David Huang initiates coverage on Avient (NYSE:AVNT) with a Buy rating and announces Price Target of $40.
HC Wainwright & Co. Initiates Coverage On Purple Biotech with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Purple Biotech (NASDAQ:PPBT) with a Buy rating and announces Price Target of $7.